Theravance and Elan Enter $1 Billion Royalty Participation Agreement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Theravance and Elan Enter $1 Billion Royalty Participation Agreement


Theravance and Elan announced in a press release that Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline (GSK): RELVAR ELLIPTA/BREO ELLIPTA (fluticasone furoate/vilanterol: FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol: UMEC/VI), MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081, or MABA '081), and vilanterol (VI) monotherapy. Under the terms of the agreement, Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from the four programs when, as, and if received by Theravance.

In April, Theravance announced plans to separate its businesses into two independent publicly traded companies: one (Royalty Management Company) to focus on managing development and commercial responsibilities under the late-stage partnered respiratory program collaboration with GSK and the second (Theravance Biopharma) to focus on discovery, development, and commercialization of small-molecule medicines in areas of significant unmet medical need. The two companies with different business models would enable investors to align their investment philosophies with the strategic opportunities and financial objectives of the two independent companies, said Theravance in the April 25, 2013 press release. The recent agreement with Elan is consistent with this plan, said Rick E Winningham, Theravance’s CEO in the May 13 press release.

"This transaction, upon closing, will immediately diversify our business with an investment in four high quality and late-stage clinical assets within a large and growing therapeutic area,” said Kelly Martin, CEO of Elan, in the May 13 press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here